<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03709953</url>
  </required_header>
  <id_info>
    <org_study_id>Spark-AL003</org_study_id>
    <nct_id>NCT03709953</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Apatinib as Third-line Therapy for Primary Pulmonary Lymphoepithelioid Carcinoma</brief_title>
  <acronym>Spark-AL003</acronym>
  <official_title>Efficacy and Safety of Apatinib as Third-line Therapy for Primary Pulmonary Lymphoepithelioid Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou Institute of Respiratory Disease</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Guangzhou Institute of Respiratory Disease</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently, there is no standard treatment for primary pulmonary lymphoepithelioid carcinoma.
      Apatinib is a new kind of Vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine
      kinase inhibitors (TKIs). A disease-control rate of 75% was found in lung cancer patients in
      a phase II clinical study. Therefore, researchers hope to explore the efficacy and safety of
      apatinib in the treatment of primary pulmonary lymphoepithelioid carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, exploratory clinical trial. The purpose of this study was to
      evaluate the efficacy and safety of apatinib monotherapy in the treatment of primary
      pulmonary lymphoepithelioid carcinoma.

      Thirty-three cases of pulmonary lymphoepithelioid carcinoma were enrolled in this study.

      The primary endpoint was median progression-free survival.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 19, 2018</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>apatinib monotherapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>24 months</time_frame>
    <description>Median progression-free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>24 months</time_frame>
    <description>Median overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>24 months</time_frame>
    <description>Objective Response Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>24 months</time_frame>
    <description>Disease control rate</description>
  </secondary_outcome>
  <other_outcome>
    <measure>KPS</measure>
    <time_frame>24 months</time_frame>
    <description>Karnofsky Performance Scale</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Lung Carcinoma</condition>
  <arm_group>
    <arm_group_label>apatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>apatinib, 500 mg, po, QD; 28 days every cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>500 mg，po，QD； 28 days every cycle</description>
    <arm_group_label>apatinib</arm_group_label>
    <other_name>Apatinib mesylate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients aged from 18 to 75;

          -  ECOG PS: 0 ~ 2 points;

          -  lung lymphoepithelioid carcinoma;

          -  Inoperable stage IV or stage III-B patients who had undergone second-line chemotherapy
             and had a measurable lesion (according to the RECIST 1.1 standard, the long diameter
             of the tumor lesion was 10mm in CT scan, the short diameter of the lymph node lesion
             was 15mm in CT scan, and the lesion was measured without local treatment such as
             radiotherapy and freezing).

          -  Life expectancy ≥3 months;

          -  the main organs are functioning normally:

               1. HB≥80 g/L(no blood transfusion within 14 days); ANC≥1.5×109 /L； PLT≥100×109 /L；
                  WBC≥3×109 /L；

               2. TBIL≤1.5×ULN (upper limit of normal value); ALT and AST ≤2.5×ULN；

               3. creatinine ≤ 1.25 ULN; The clearance rate of creatinine ≥ 60mL/min.

               4. 24-hour urinary protein quantification &lt; 1.0g;

          -  women of reproductive age (15 to 49 years old) must undergo a urinary pregnancy test
             within 7 days before starting treatment and the results must be negative. Women are
             willing to use appropriate methods of contraception;

          -  Subjects signed the informed consent voluntarily.

        Exclusion Criteria:

          -  Histologically proved to be other types of lung cancer, patients with nasopharyngeal
             lymphatic epithelial carcinoma with lung metastasis should be excluded.

          -  Imperfection of upper gastrointestinal physiology, or absorption disorder syndrome, or
             inability to tolerate oral drugs, or active peptic ulcer;

          -  Participated in other clinical trials within 4 weeks before the start of the study;

          -  patients with hypertension who cannot control well through single antihypertensive
             medication (systolic blood pressure &gt; 140mmhg, diastolic blood pressure &gt; 90mmhg),
             myocardial ischemia or myocardial infarction, arrhythmia (including QT interval &gt; 440
             ms) or cardiac insufficiency;

          -  Allergic to any ingredient in the drug;

          -  Patients with abnormal coagulation function, receiving thrombolysis or anticoagulation
             therapy, bleeding tendency or have clear gastrointestinal bleeding concerns;

          -  Hyperactive/venous thrombosis events, such as cerebrovascular accident (including
             transient ischemic attack), deep venous thrombosis and pulmonary embolism occurred in
             6 months before the start of the study;

          -  Wound or fracture has not been healed for a long time;

          -  urinary protein was greater than ++ and 24-hour urinary protein quantification ＞1.0 g.

          -  Severe or uncontrolled infections;

          -  Substance abuse or mental disorder;

          -  Objective evidence of a history of pulmonary fibrosis, interstitial pneumonia,
             pneumoconiosis, radioactive pneumonia, drug-related pneumonia, and severe impairment
             of pulmonary function;

          -  Immunodeficiency, including being HIV-positive, or having other acquired, congenital
             immunodeficiency diseases, or having a history of organ transplantation;

          -  Other malignant tumors within 5 years, except cured basal cell carcinoma of the skin
             and orthotopic carcinoma of the cervix;

          -  Who have received VEGFR inhibitors, such as sorafenib and sunitinib, etc.;

          -  pregnant or lactating women;

          -  the researchers considered it unsuitable for inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chengzhi Zhou, professor</last_name>
    <phone>13560351186</phone>
    <email>doctorzcz@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhou Chengzhi</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chengzhi Zhou, Professor</last_name>
      <phone>13560351186</phone>
      <email>doctorzcz@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Bégin LR, Eskandari J, Joncas J, Panasci L. Epstein-Barr virus related lymphoepithelioma-like carcinoma of lung. J Surg Oncol. 1987 Dec;36(4):280-3.</citation>
    <PMID>2826922</PMID>
  </reference>
  <reference>
    <citation>Ngan RK, Yip TT, Cheng WW, Chan JK, Cho WC, Ma VW, Wan KK, Au JS, Law CK. Clinical role of circulating Epstein-Barr virus DNA as a tumor marker in lymphoepithelioma-like carcinoma of the lung. Ann N Y Acad Sci. 2004 Jun;1022:263-70.</citation>
    <PMID>15251971</PMID>
  </reference>
  <reference>
    <citation>Lin L, Lin T, Zeng B. Primary lymphoepithelioma-like carcinoma of the lung: An unusual cancer and clinical outcomes of 14 patients. Oncol Lett. 2017 Sep;14(3):3110-3116. doi: 10.3892/ol.2017.6510. Epub 2017 Jun 30.</citation>
    <PMID>28928848</PMID>
  </reference>
  <reference>
    <citation>Kim C, Rajan A, DeBrito PA, Giaccone G. Metastatic lymphoepithelioma-like carcinoma of the lung treated with nivolumab: a case report and focused review of literature. Transl Lung Cancer Res. 2016 Dec;5(6):720-726. doi: 10.21037/tlcr.2016.11.06.</citation>
    <PMID>28149767</PMID>
  </reference>
  <reference>
    <citation>Khokhar N, Nasir H, Amir M, Hassan S, Khan K, Ahmed M. Lymphoepithelioma-Like Carcinoma of the Esophagus: A Rare Tumor. J Coll Physicians Surg Pak. 2017 Sep;27(9):S114-S116. doi: 279.</citation>
    <PMID>28969745</PMID>
  </reference>
  <reference>
    <citation>Lin CY, Chen YJ, Hsieh MH, Wang CW, Fang YF. Advanced primary pulmonary lymphoepithelioma-like carcinoma: clinical manifestations, treatment, and outcome. J Thorac Dis. 2017 Jan;9(1):123-128. doi: 10.21037/jtd.2017.01.25.</citation>
    <PMID>28203414</PMID>
  </reference>
  <reference>
    <citation>Ooi GC, Ho JC, Khong PL, Wong MP, Lam WK, Tsang KW. Computed tomography characteristics of advanced primary pulmonary lymphoepithelioma-like carcinoma. Eur Radiol. 2003 Mar;13(3):522-6. Epub 2002 Jul 16.</citation>
    <PMID>12594554</PMID>
  </reference>
  <reference>
    <citation>Mo Y, Shen J, Zhang Y, Zheng L, Gao F, Liu L, Xie C. Primary lymphoepithelioma-like carcinoma of the lung: distinct computed tomography features and associated clinical outcomes. J Thorac Imaging. 2014 Jul;29(4):246-51. doi: 10.1097/RTI.0000000000000070.</citation>
    <PMID>24463405</PMID>
  </reference>
  <reference>
    <citation>Ma H, Wu Y, Lin Y, Cai Q, Ma G, Liang Y. Computed tomography characteristics of primary pulmonary lymphoepithelioma-like carcinoma in 41 patients. Eur J Radiol. 2013 Aug;82(8):1343-6. doi: 10.1016/j.ejrad.2013.02.006. Epub 2013 Mar 5.</citation>
    <PMID>23465736</PMID>
  </reference>
  <reference>
    <citation>Tian S, Quan H, Xie C, Guo H, Lü F, Xu Y, Li J, Lou L. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci. 2011 Jul;102(7):1374-80. doi: 10.1111/j.1349-7006.2011.01939.x. Epub 2011 May 9.</citation>
    <PMID>21443688</PMID>
  </reference>
  <reference>
    <citation>Jeong JH, Nguyen HK, Lee JE, Suh W. Therapeutic effect of apatinib-loaded nanoparticles on diabetes-induced retinal vascular leakage. Int J Nanomedicine. 2016 Jul 7;11:3101-9. doi: 10.2147/IJN.S108452. eCollection 2016.</citation>
    <PMID>27462154</PMID>
  </reference>
  <reference>
    <citation>Mi YJ, Liang YJ, Huang HB, Zhao HY, Wu CP, Wang F, Tao LY, Zhang CZ, Dai CL, Tiwari AK, Ma XX, To KK, Ambudkar SV, Chen ZS, Fu LW. Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. Cancer Res. 2010 Oct 15;70(20):7981-91. doi: 10.1158/0008-5472.CAN-10-0111. Epub 2010 Sep 28.</citation>
    <PMID>20876799</PMID>
  </reference>
  <reference>
    <citation>Tong XZ, Wang F, Liang S, Zhang X, He JH, Chen XG, Liang YJ, Mi YJ, To KK, Fu LW. Apatinib (YN968D1) enhances the efficacy of conventional chemotherapeutical drugs in side population cells and ABCB1-overexpressing leukemia cells. Biochem Pharmacol. 2012 Mar 1;83(5):586-97. doi: 10.1016/j.bcp.2011.12.007. Epub 2011 Dec 16.</citation>
    <PMID>22212563</PMID>
  </reference>
  <reference>
    <citation>Song Z, Yu X, Lou G, Shi X, Zhang Y. Salvage treatment with apatinib for advanced non-small-cell lung cancer. Onco Targets Ther. 2017 Mar 23;10:1821-1825. doi: 10.2147/OTT.S113435. eCollection 2017.</citation>
    <PMID>28367065</PMID>
  </reference>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 11, 2018</study_first_submitted>
  <study_first_submitted_qc>October 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2018</study_first_posted>
  <last_update_submitted>October 23, 2018</last_update_submitted>
  <last_update_submitted_qc>October 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangzhou Institute of Respiratory Disease</investigator_affiliation>
    <investigator_full_name>Zhou Chengzhi</investigator_full_name>
    <investigator_title>Director, Head of pneumology department, Principal Investigator, Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>apatinib</keyword>
  <keyword>pulmonary lymphoepithelioid carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Update after discussion</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

